Navigation Links
The Contract Biomanufacturing Market Outlook to 2017
Date:3/7/2013

NEW YORK, March 7, 2013 /PRNewswire/ --Reportlinker.com announces that a new market research report is available in its catalogue:

The Contract Biomanufacturing Market Outlook to 2017
http://www.reportlinker.com/p01118464/The-Contract-Biomanufacturing-Market-Outlook-to-2017.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Biopharmaceutical

Introduction

The volume demand for biologics active pharmaceutical ingredients (API) from 2011-2017 is set to show a 20% annual increase. Combined with a boost in biosimilars, the biologics contract manufacturing market is forecast to grow 9% per year over the same period.

Scope

• Develop a winning expansion and outsourcing strategy to grow your market share with forecasts through to 2017
• Assess the areas to target and use your findings to help increase profits with information on drivers and resistors of outsourced biomanufacturing
• Use the forecast for biologic and CMO market to adapt your strategy and ensure you're commercially successful
• With analysis on the 5 leading players you will understand what your competitors are doing and what actions you can take to stay competitive
The biological contract manufacturing organization (CMO) market will grow at a compound annual growth rate (CAGR) of 9.4% between 2011 and 2017. Mammalian contract manufacturing accounted for almost two thirds of the market in 2012, which was estimated at a size of $3bn.

Increasing API demand driven by biologics market growth and an increase in the number of late-stage clinical trials and approved biotech products will be the biggest drivers of the bio-CMO market.

Reasons to Buy

• What is the state of contract biomanufacturing in emerging regions?
• Who are the leading bio-CMOs and what are their strategies, strengths and weaknesses?
• What is the most attractive area of investment in the biologics market?

Table of Contents

Overview 4
Catalyst 4
–– Summary 4
Executive Summary 5
Market Overview 6
Definition 6
Segmentation 6
–– Categories of CMOs and services offered 7
References 9
Market Dynamics 10
Drivers 10
–– Growth of large molecule market 10
–– Cost savings 11
–– Risk reduction and risk sharing 11
–– Lead-time saving 11
–– Access to expertise and technology 12
–– Orphan drugs 12
–– Growth in emerging markets 13
–– Biosimilars 13
Resistors 14
–– Increasing yields and disposable technology 14
–– Overcapacity and pharma's increasing in-house capacity 14
–– Regulatory uncertainty over biosimilars 14
Market forecasts 15
–– Microbial and mammalian drug market 15
–– Microbial vs mammalian CMO market 15
–– Biosimilars 15
–– Biomanufacturing installed base 16
Contract biomanufacturing in emerging regions 17
References 17
Leading Players 19
Summary 19
Introduction 19
Boehringer Ingelheim 20
–– Overview and capabilities 20
–– Partnerships, deals, and expansion plans 20
–– SWOT analysis 21
Lonza 21
–– Overview and capabilities 21
–– Partnerships, deals, and expansion plans 22
–– SWOT analysis 22
Sandoz 23
–– Overview and capabilities 23
–– Partnerships, deals, and expansion plans 23
–– SWOT analysis 23
Fujifilm Diosynth Biotechnologies 24
–– Overview and capabilities 24
–– Partnerships, deals, and expansion plans 24
–– SWOT analysis 24
DSM 25
–– Overview and capabilities 25
–– Partnerships, deals, and expansion plans 25
–– SWOT analysis 26
References 26
Appendix 29
Methodology 29
–– Pharmaceutical market 29
–– Bio-CMO market 29
References 29
Table 1: Categories of CMOs and services offered 7
Figure 1: Biopharma value chain 7
Figure 2: Small vs large molecule pharma market ($bn), 2008–17 10
Figure 3: Number of orphan drug NMEs historically and
forecasted average in the US, 2005–16 12
Figure 4: Biopharmaceutical drug market by major product
group ($bn), 2011–17 15
Figure 5: Mammalian and microbial API CMO market ($bn),
2010–17 16
Figure 6: Comparison of leading bio-CMOs by capability 19

Companies Mentioned

First Aviation Services Inc., Hutchison 3G UK Limited

To order this report:
Biopharmaceutical Industry: The Contract Biomanufacturing Market Outlook to 2017

_________________________
Contact Clare: clare@reportlinker.com
US:(339) 368 6001
Intl:+1 339 368 6001


'/>"/>
SOURCE Reportlinker
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Watchdog Organization Releases Toolkit to Help Employers Navigate Pharmacy Benefits Contracts
2. Groupe Athena, Inc. Enters Multi Year Contractual Relationship With Major Bangladesh Pharmaceutical Manufacturer
3. Medical Device Contract Manufacturing: World Market Outlook 2013-2023
4. Romark Laboratories Awarded Contract For Late-Stage Development Of New Influenza Drug
5. CliniComp Announces Contract Wins With Daughters of Charity Health System
6. Odyssey Thera, Inc. Announces New Equity Financing and Initiation of Research Contract with Merck
7. Comprehensive Care Corporation Announces New Medicare Contract with Humana Health Plan of California, Inc.
8. Contract Manufacturing Organizations to 2018 - Cost Advantages and Improving Quality Standards Build Confidence and Encourage Foreign Investment in Asian CMOs
9. Contract Research Organisations offer Promise of Innovative, Safe and Effective Drug Development, Says Frost & Sullivan
10. Global BioClinical Awarded Cancer Genome Atlas (TCGA) Contract
11. National Institute of Health Awards Contract to Support Use of iBios Proprietary Technology for Improved Anthrax Vaccine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... , April 20, 2017 Research and Markets ... - Innovation Driven by Rapidly Expanding Injectables Market and Increasing Usage ... offering. ... drug delivery technologies will rise from USD 20 Billion in 2015 ... Global Drug Delivery Technologies - Innovation Driven by Rapidly Expanding Injectables ...
(Date:4/20/2017)...  AbbVie (NYSE: ABBV), a global biopharmaceutical company, ... hepatitis C virus (HCV) infected patients with genotype ... cirrhosis (Child-Pugh A) achieved sustained virologic response at ... investigational, pan-genotypic regimen of glecaprevir/pibrentasvir (G/P). These high ... weeks of G/P treatment without ribavirin. Patients with ...
(Date:4/20/2017)... LUND, Sweden , April 20, 2017 /PRNewswire/ ... OTCQX: NEVPF) ("NeuroVive") today announced positive preclinical ... company,s preclinical compound for non-alcoholic steatohepatitis (NASH), ... NV556 has previously ... STAM™ NASH model. Today, NeuroVive,s scientists present ...
Breaking Medicine Technology:
(Date:4/28/2017)... NC (PRWEB) , ... April 28, 2017 , ... ... announce its new partnership with the Home Care Association of America (HCAOA). This ... and Private Duty Accreditation services, as well as discounts on Accreditation University (AU) ...
(Date:4/28/2017)... , ... April 28, 2017 , ... Getting enough sleep affects much more than energy ... going just 19 hours without sleep can compromise motor reaction time, which can increase the ... Amica Insurance is sharing the following tips from the NSF to help you sleep better ...
(Date:4/28/2017)... ... April 28, 2017 , ... ... Patel M.D. has joined the revolutionary endoscopic practice under Dr. Datta. Patel is ... Interventional Pain Medicine. The patented, revolutionary eDiscSculpt Technique created and used by Datta ...
(Date:4/28/2017)... ... ... People are starting to accept that hearing aids can be helpful and are ... had when great-grandpa wore his hearing aids years ago,” said Dr. Maura Marks, founder ... Speaker Series (NASS) segment. “He probably wore an iPod-size hearing aid on his ...
(Date:4/28/2017)... ... April 28, 2017 , ... ... assisting the Brooke Grove Foundation implement a Microsoft Dynamics GP solution that integrates ... leading ERP expert that specializes in long-term care, Brooke Grove now has the ...
Breaking Medicine News(10 mins):